Information non disponible
- Bouaou, Ania MelissaEmployéaniaemail@example.com
Determinants of guideline-concordant breast cancer screening by family physicians for women aged 40-49 years: a qualitative analysisArticle de revue
CMAJ Open, 10 (4), 2022.
Fragility index of trials supporting approval of anti-cancer drugs in common solid tumoursArticle de revue
Cancer Treat Rev, 94 , 2021.
Implementing DPYD*2A Genotyping in Clinical Practice: The Quebec, Canada, ExperienceArticle de revue
Oncologist, 26 (4), 2021.
Network Meta-analysis Comparing Efficacy, Safety and Tolerability of Anti-PD-1/PD-L1 Antibodies in Solid CancersArticle de revue
J Cancer, 12 (14), 2021.
Adjuvant Zoledronate Therapy for Women With Breast Cancer-Effective Treatment or Fool's Gold?Article de revue
JAMA Oncol, 7 (8), 2021.
Fragility of randomized trials supporting cancer drug approvals stratified by approval pathway and review designationsArticle de revue
Cancer Med, 10 (16), 2021.
Quantifying Withdrawal of Consent, Loss to Follow-Up, Early Drug Discontinuation, and Censoring in Oncology TrialsArticle de revue
J Natl Compr Canc Netw, 19 (12), 2021.
Patient and provider determinants of breast cancer screening among Ontario women aged 40-49: a population-based retrospective cohort studyArticle de revue
Breast Cancer Res Treat, 189 (3), 2021.
Platinum-based chemotherapy in early-stage triple negative breast cancer: A meta-analysisArticle de revue
Cancer Treat Rev, 100 , 2021.
Influence of Competing Risks on Estimates of Recurrence Risk and Breast Cancer-specific Mortality in Analyses of the Early Breast Cancer Trialists Collaborative GroupArticle de revue
Sci Rep, 10 (1), 2020.